Document is current
Any future updates will be listed below
-
Authors
Jurkunas, Ula V. https://orcid.org/0000-0002-5059-608X
Kaufman, Aaron R.
Yin, Jia https://orcid.org/0000-0003-1340-6758
Ayala, Allison
Maguire, Maureen https://orcid.org/0000-0002-4249-2467
Samarakoon, Lassana
Johns, Lynette K.
Parekh, Mohit https://orcid.org/0000-0002-5186-068X
Li, Sanming
Gauthier, Alex
Negre, Helene
Shaw, Kit L.
Hernandez Rodriguez, Diego E.
Daley, Heather
Dana, Reza https://orcid.org/0000-0002-5732-5100
Armant, Myriam https://orcid.org/0000-0002-5205-3003
Ritz, Jerome https://orcid.org/0000-0001-5526-4669
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Eye Institute (UG1EY027726, UG1EY027725)
- License Information
-
More Information
Article History
Received: 13 June 2024
Accepted: 17 January 2025
First Online: 4 March 2025
Competing interests
: Patent pending (UVJ, R.D., J.R., and M.A.). U.V.J. and R.D. have financial interests in OcuCell, Inc. This company is developing living ophthalmic cell-based therapies for treating eye disease. U.V.J. and R.D. interests were reviewed and are managed by Mass Eye and Ear Infirmary and Mass General Brigham in accordance with their competing interest policies. M.A. serves on the scientific advisory board for OcuCell, Inc. JR receives research funding from Kite/Gilead, Novartis and Oncternal and serves on Scientific Advisory Boards for Astraveus, Garuda Therapeutics, LifeVault Bio, Smart Immune, Tolerance Bio, and TriArm Therapeutics. ARK, JY, AA, MM, LS, LKJ, MP, SL, AG, HN, KLS, DEHH, and HD declare no competing interests.
